551
Participants
Start Date
October 31, 2007
Primary Completion Date
July 31, 2008
Study Completion Date
September 30, 2008
Nasal Placebo
Nasal placebo, three times a day, 30 minutes before a meal for 24 weeks.
Placebo Capsule
Placebo capsules will be taken once daily with or without food.
PYY3-36
Nasal PYY3-36, three times a day, 30 minutes before a meal for 24 weeks.
PYY3-36
Nasal PYY3-36 three times a day, 30 minutes before a meal for 24 weeks.
PYY3-36
Nasal PYY3-36 three times a day, 30 minutes before a meal for 24 weeks.
Sibutramine
Sibutramine will be taken once daily with or without food
For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Manlius
For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Reading
For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Raleigh
For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Charlotte
For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Mt. Pleasant
For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Greer
For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Atlanta
For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Augusta
For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Pembroke Pines
For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Cleveland
For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Valparaiso
For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Evansville
For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Brooklyn Center
For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Baton Rouge
For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Temple
For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Austin
For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Salt Lake City
For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Phoenix
For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Peoria
For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Las Vegas
For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Beverly Hills
For additional information regarding investigative sites for this trial, contact 1-425-415-3011, San Diego
For additional information regarding investigative sites for this trial, contact 1-425-415-3011, San Diego
For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Anaheim
For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Orange
For additional information regarding investigative sites for this trial, contact 1-425-415-3011, San Francisco
For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Carmichael
For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Sacramento
For additional information regarding investigative sites for this trial, contact 1-425-415-3011, San Antonio
Lead Sponsor
Nastech Pharmaceutical Company, Inc.
INDUSTRY